HUTCHMED (China) Ltd

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for oncology and immunological diseases. The company's marketed products include Fruquintinib, a vascular endothelial growth factor receptor inhibitor approved for multiple cancer indications including colorectal, breast, gastric, and non-small cell lung cancer, and Savolitinib, a mesenchymal-epithelial transition receptor inhibitor for non-small cell lung cancer and renal cell carcinoma. The pipeline includes Surufatinib for neuroendocrine and pancreatic tumors, Sovleplenib for immune thrombocytopenic purpura and autoimmune hemolytic anemia, and several molecules in earlier development stages targeting hematologic malignancies and solid tumors.

The company operates through partnerships with major pharmaceutical companies including AstraZeneca, Eli Lilly, Takeda, and BeiGene, which provide both development collaboration and commercialization support. HUTCHMED maintains a research and development infrastructure with approximately 1,780 full-time employees and operates across Hong Kong, the United States, and international markets. The company was incorporated in the Cayman Islands in 2000 and is headquartered in Hong Kong, with dual listing on Nasdaq providing access to North American capital markets.